Replies to post #10121 on Ariad Pharmaceuticals Inc fka ARIA

[BTH]

I continue to be both amused and encouraged by how so many of these general media biopharma reporters don't even mention 113 as part of Ariad's portfolio-

Yes. Ponatinib speculation got us to $12 (and certainly more room IMO). Now, it's time for '113 to goose this pig to $20.